Objectif The Zebrafish Lab is a biotechnological company leader in the development and commercialization of novel, tailor-made solutions based on in vivo zebrafish assays. Thanks to the extensive knowledge acquired by the R&D projects performed in the field by our team for many years and a close collaboration with Hospitals and Cancer Research Institutions, we have identified a remarkable opportunity in MY FISH CURE project that will mean a 5-year after tax-R.O.I of 490% according to our estimations. The ultimate goal of the project presented as MY FISH CURE is to complete the clinical studies required to bring to the healthcare market a novel real time in vivo platform for personalized cancer treatment based on the use of zebrafish “avatars” as personalized, living test tubes. Cancer is a leading cause of morbidity and mortality with approx. 35 million people affected by this disease and more than 7 million deaths per year. A major difficulty found in effective cancer treatment is the complexity of the biological mechanism underlying cancer onset and disease progression. As such, different people respond differently to the same therapy. Personalized cancer therapy can provide a solution to these challenges in cancer treatment. In MY FISH CURE project we seek overcoming the mayor barriers currently preventing the use of zebrafish avatars as in vivo models for patient-directed interventions, so for their use in a clinical context instead of a research or drug development context. Thanks to MY FISH CURE project, we will become the first company in the world offering zebrafish avatar models for personalized cancer care. Champ scientifique medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverysocial sciencessociologydemographymortalitymedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsmedical and health sciencesclinical medicineoncologymedical and health scienceshealth sciencespersonalized medicine Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Thème(s) SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector Appel à propositions H2020-SMEInst-2016-2017 Voir d’autres projets de cet appel Sous appel H2020-SMEINST-1-2016-2017 Régime de financement SME-1 - SME instrument phase 1 Coordinateur IKAN BIOTECH S.L. Contribution nette de l'UE € 50 000,00 Adresse CALLE CHAPITELA 20 1 31001 PAMPLONA Espagne Voir sur la carte PME L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention. Oui Région Noreste Comunidad Foral de Navarra Navarra Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Liens Contacter l’organisation Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 71 429,00
